|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chemoradiotherapy for Cervical Cancer
Meta-Analysis Collaboration, . Reducing uncertainties about the
effects of chemoradiotherapy for cervical cancer: A systematic
review and meta-analysis of individual patient data from 18
randomized trials. J Clin Oncol. 26:5802–5812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Green JA, Kirwan JM, Tierney JF, Symonds
P, Fresco L, Collingwood M and Williams CJ: Survival and recurrence
after concomitant chemotherapy and radiotherapy for cancer of the
uterine cervix: A systematic review and meta-analysis. Lancet.
358:781–786. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Quinn MA, Benedet JL, Odicino F,
Maisonneuve P, Beller U, Creasman WT, Heintz AP, Ngan HY and
Pecorelli S: Carcinoma of the cervix uteri. Int J Gynaecol Obstet.
95 (Suppl 1):S43–S103. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee Y, Kim SH, Han JY, Kim HT, Yun T and
Lee JS: Early neutrophil-to-lymphocyte ratio reduction as a
surrogate marker of prognosis in never smokers with advanced lung
adenocarcinoma receiving gefitinib or standard chemotherapy as
first-line therapy. J Cancer Res Clin Oncol. 138:2009–2016. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Balkwill F and Mantovani A: Inflammation
and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aliustaoglu M, Bilici A, Seker M, Dane F,
Gocun M, Konya V, Ustaalioglu BB and Gumus M: The association of
pre-treatment peripheral blood markers with survival in patients
with pancreatic cancer. Hepatogastroenterology. 57:640–645.
2010.PubMed/NCBI
|
|
8
|
Azab B, Bhatt VR, Phookan J, Murukutla S,
Kohn N, Terjanian T and Widmann WD: Usefulness of the
neutrophil-to-lymphocyte ratio in predicting short- and long-term
mortality in breast cancer patients. Ann Surg Oncol. 19:217–224.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kishi Y, Kopetz S, Chun YS, Palavecino M,
Abdalla EK and Vauthey JN: Blood neutrophil-to-lymphocyte ratio
predicts survival in patients with colorectal liver metastases
treated with systemic chemotherapy. Ann Surg Oncol. 16:614–622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sarraf KM, Belcher E, Raevsky E, Nicholson
AG, Goldstraw P and Lim E: Neutrophil/lymphocyte ratio and its
association with survival after complete resection in non-small
cell lung cancer. J Thorac Cardiovasc Surg. 137:425–428. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yamanaka T, Matsumoto S, Teramukai S,
Ishiwata R, Nagai Y and Fukushima M: The baseline ratio of
neutrophils to lymphocytes is associated with patient prognosis in
advanced gastric cancer. Oncology. 73:215–220. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang CS and Sun CF: C-reactive protein and
malignancy: Clinico-pathological association and therapeutic
implication. Chang Gung Med J. 32:471–482. 2009.PubMed/NCBI
|
|
13
|
Kesic V: Management of cervical cancer.
Eur J Surg Oncol. 32:832–837. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cadron I, Van Gorp T, Amant F, Leunen K,
Neven P and Vergote I: Chemotherapy for recurrent cervical cancer.
Gynecol Oncol. 107 (Suppl 1):S113–S118. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bonomi P, Blessing JA, Stehman FB, DiSaia
PJ, Walton L and Major FJ: Randomized trial of three cisplatin dose
schedules in squamous-cell carcinoma of the cervix: A Gynecologic
Oncology Group study. J Clin Oncol. 3:1079–1085. 1985.PubMed/NCBI
|
|
16
|
Thigpen JT, Blessing JA, Fowler WC Jr and
Hatch K: Phase II trials of cisplatin and piperazinedione as single
agents in the treatment of advanced or recurrent non-squamous cell
carcinoma of the cervix: A Gynecologic Oncology Group Study. Cancer
Treat Rep. 70:1097–1100. 1986.PubMed/NCBI
|
|
17
|
Arseneau J, Blessing JA, Stehman FB and
McGehee R: A phase II study of carboplatin in advanced squamous
cell carcinoma of the cervix (a Gynecologic Oncology Group Study).
Invest New Drugs. 4:187–191. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McGuire WP III, Arseneau J, Blessing JA,
DiSaia PJ, Hatch KD, Given FT Jr, Teng NN and Creasman WT: A
randomized comparative trial of carboplatin and iproplatin in
advanced squamous carcinoma of the uterine cervix: A Gynecologic
Oncology Group study. J Clin Oncol. 7:1462–1468. 1989.PubMed/NCBI
|
|
19
|
Schilder RJ, Blessing JA, Morgan M, Mangan
CE and Rader JS: Evaluation of gemcitabine in patients with
squamous cell carcinoma of the cervix: A Phase II study of the
gynecologic oncology group. Gynecol Oncol. 76:204–207. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schilder RJ, Blessing J and Cohn DE:
Evaluation of gemcitabine in previously treated patients with
non-squamous cell carcinoma of the cervix: A phase II study of the
Gynecologic Oncology Group. Gynecol Oncol. 96:103–107. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kudelka AP, Winn R, Edwards CL, Downey G,
Greenberg H, Dakhil SR, Freedman RS, Loyer E, Rusinkiewicz J,
Gacrama P, et al: Activity of paclitaxel in advanced or recurrent
squamous cell cancer of the cervix. Clin Cancer Res. 2:1285–1288.
1996.PubMed/NCBI
|
|
22
|
Kudelka AP, Winn R, Edwards CL, Downey G,
Greenberg H, Dakhil SR, Freedman RS, LoCoco S, Umbreit J, Delmore
JE, et al: An update of a phase II study of paclitaxel in advanced
or recurrent squamous cell cancer of the cervix. Anticancer Drugs.
8:657–661. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Verschraegen CF, Levy T, Kudelka AP,
Llerena E, Ende K, Freedman RS, Edwards CL, Hord M, Steger M,
Kaplan AL, et al: Phase II study of irinotecan in prior
chemotherapy-treated squamous cell carcinoma of the cervix. J Clin
Oncol. 15:625–631. 1997.PubMed/NCBI
|
|
24
|
Lhommé C, Fumoleau P, Fargeot P, Krakowski
Y, Dieras V, Chauvergne J, Vennin P, Rebattu P, Roche H, Misset JL,
et al: Results of a European Organization for Research and
Treatment of Cancer/Early Clinical Studies Group phase II trial of
first-line irinotecan in patients with advanced or recurrent
squamous cell carcinoma of the cervix. J Clin Oncol. 17:3136–3142.
1999.PubMed/NCBI
|
|
25
|
Rose PG, Blessing JA, Gershenson DM and
McGehee R: Paclitaxel and cisplatin as first-line therapy in
recurrent or advanced squamous cell carcinoma of the cervix: A
gynecologic oncology group study. J Clin Oncol. 17:2676–2680.
1999.PubMed/NCBI
|
|
26
|
Papadimitriou CA, Sarris K, Moulopoulos
LA, Fountzilas G, Anagnostopoulos A, Voulgaris Z, Gika D,
Giannakoulis N, Diakomanolis E and Dimopoulos MA: Phase II trial of
paclitaxel and cisplatin in metastatic and recurrent carcinoma of
the uterine cervix. J Clin Oncol. 17:761–766. 1999.PubMed/NCBI
|
|
27
|
Piver MS, Ghamande SA, Eltabbakh GH and
O'Neill-Coppola C: First-line chemotherapy with paclitaxel and
platinum for advanced and recurrent cancer of the cervix - a phase
II study. Gynecol Oncol. 75:334–337. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tinker AV, Bhagat K, Swenerton KD and
Hoskins PJ: Carboplatin and paclitaxel for advanced and recurrent
cervical carcinoma: The British Columbia Cancer Agency experience.
Gynecol Oncol. 98:54–58. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pectasides D, Fountzilas G, Papaxoinis G,
Pectasides E, Xiros N, Sykiotis C, Koumarianou A, Psyrri A,
Panayiotides J and Economopoulos T: Carboplatin and paclitaxel in
metastatic or recurrent cervical cancer. Int J Gynecol Cancer.
19:777–781. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saito I, Kitagawa R, Fukuda H, Shibata T,
Katsumata N, Konishi I, Yoshikawa H and Kamura T: A phase III trial
of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in
stage IVB, persistent or recurrent cervical cancer: Gynecologic
Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505).
Jpn J Clin Oncol. 40:90–93. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jackson JR, Seed MP, Kircher CH,
Willoughby DA and Winkler JD: The codependence of angiogenesis and
chronic inflammation. FASEB J. 11:457–465. 1997.PubMed/NCBI
|
|
32
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Assoian RK and Sporn MB: Type beta
transforming growth factor in human platelets: Release during
platelet degranulation and action on vascular smooth muscle cells.
J Cell Biol. 102:1217–1223. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kaplan KL, Broekman MJ, Chernoff A,
Lesznik GR and Drillings M: Platelet alpha-granule proteins:
Studies on release and subcellular localization. Blood. 53:604–618.
1979.PubMed/NCBI
|
|
35
|
Hefler LA, Zeillinger R, Grimm C, Sood AK,
Cheng WF, Gadducci A, Tempfer CB and Reinthaller A: Preoperative
serum vascular endothelial growth factor as a prognostic parameter
in ovarian cancer. Gynecol Oncol. 103:512–517. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tempfer C, Zeisler H, Sliutz G, Haeusler
G, Hanzal E and Kainz C: Serum evaluation of interleukin 6 in
ovarian cancer patients. Gynecol Oncol. 66:27–30. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee YY, Choi CH, Kim HJ, Kim TJ, Lee JW,
Lee JH, Bae DS and Kim BG: Pretreatment neutrophil:lymphocyte ratio
as a prognostic factor in cervical carcinoma. Anticancer Res.
32:1555–1561. 2012.PubMed/NCBI
|
|
38
|
Zhang Y, Wang L, Liu Y, Wang S, Shang P,
Gao Y and Chen X: Preoperative neutrophil-lymphocyte ratio before
platelet-lymphocyte ratio predicts clinical outcome in patients
with cervical cancer treated with initial radical surgery. Int J
Gynecol Cancer. 24:1319–1325. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Polterauer S, Grimm C, Tempfer C, Sliutz
G, Speiser P, Reinthaller A and Hefler LA: C-reactive protein is a
prognostic parameter in patients with cervical cancer. Gynecol
Oncol. 107:114–117. 2007. View Article : Google Scholar : PubMed/NCBI
|
